Market Closed -
Xetra
09:05:37 31/05/2024 pm IST
|
5-day change
|
1st Jan Change
|
4.112
EUR
|
+2.24%
|
|
+5.33%
|
-13.41%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
233.7
|
704.9
|
2,574
|
861.1
|
655.1
|
572.5
|
-
|
-
|
Enterprise Value (EV)
1 |
195.5
|
553.9
|
2,286
|
670.5
|
737.8
|
650.2
|
666.6
|
688.3
|
P/E ratio
|
-129
x
|
-10.9
x
|
-32.7
x
|
-5.02
x
|
-6.47
x
|
37.4
x
|
-53.1
x
|
-22
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
0.24%
|
-
|
Capitalization / Revenue
|
1.85
x
|
6.39
x
|
7.4
x
|
2.38
x
|
4.26
x
|
3.01
x
|
2.45
x
|
1.78
x
|
EV / Revenue
|
1.55
x
|
5.02
x
|
6.57
x
|
1.86
x
|
4.8
x
|
3.42
x
|
2.85
x
|
2.14
x
|
EV / EBITDA
|
25.1
x
|
-12.3
x
|
-48.5
x
|
-9.69
x
|
-11.3
x
|
13
x
|
-27.4
x
|
-272
x
|
EV / FCF
|
-36.5
x
|
4.68
x
|
-140
x
|
-2.44
x
|
-3.4
x
|
-30.1
x
|
-668
x
|
200
x
|
FCF Yield
|
-2.74%
|
21.4%
|
-0.71%
|
-41%
|
-29.4%
|
-3.32%
|
-0.15%
|
0.5%
|
Price to Book
|
1.73
x
|
9.09
x
|
15.1
x
|
-
|
5.1
x
|
3.31
x
|
4.86
x
|
5.77
x
|
Nbr of stocks (in thousands)
|
90,920
|
90,958
|
1,05,078
|
1,38,355
|
1,38,788
|
1,39,153
|
-
|
-
|
Reference price
2 |
2.570
|
7.750
|
24.50
|
6.224
|
4.720
|
4.114
|
4.114
|
4.114
|
Announcement Date
|
27/02/20
|
25/02/21
|
03/02/22
|
23/03/23
|
21/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
126.2
|
110.3
|
348.1
|
361.3
|
153.7
|
190
|
233.6
|
321.8
|
EBITDA
1 |
7.8
|
-45.2
|
-47.1
|
-69.2
|
-65.24
|
49.92
|
-24.3
|
-2.532
|
EBIT
1 |
-0.811
|
-55.12
|
-61.4
|
-113.4
|
-82.09
|
27.48
|
-31.77
|
-11.95
|
Operating Margin
|
-0.64%
|
-49.97%
|
-17.64%
|
-31.4%
|
-53.4%
|
14.46%
|
-13.6%
|
-3.71%
|
Earnings before Tax (EBT)
1 |
-0.87
|
-65.3
|
-69.98
|
-144.8
|
-98.63
|
-0.9092
|
-47.79
|
-18.11
|
Net income
1 |
-1.7
|
-64.4
|
-73.4
|
-143.3
|
-101.4
|
6.721
|
-29.08
|
-22.63
|
Net margin
|
-1.35%
|
-58.39%
|
-21.09%
|
-39.66%
|
-65.99%
|
3.54%
|
-12.45%
|
-7.03%
|
EPS
2 |
-0.0200
|
-0.7100
|
-0.7500
|
-1.240
|
-0.7300
|
0.1100
|
-0.0775
|
-0.1867
|
Free Cash Flow
1 |
-5.355
|
118.3
|
-16.27
|
-274.7
|
-217
|
-21.57
|
-0.9976
|
3.439
|
FCF margin
|
-4.24%
|
107.22%
|
-4.67%
|
-76.02%
|
-141.16%
|
-11.35%
|
-0.43%
|
1.07%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
0.0100
|
-
|
Announcement Date
|
27/02/20
|
25/02/21
|
03/02/22
|
23/03/23
|
21/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020 S1
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
47.91
|
278.3
|
21.8
|
71.4
|
93.2
|
156.7
|
111.4
|
33.51
|
40.19
|
38.07
|
41.9
|
32.75
|
41.38
|
43.63
|
55.36
|
EBITDA
|
-
|
12.54
|
-13.3
|
-122.7
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-21.93
|
11.1
|
-18.4
|
-128.8
|
-147.2
|
93.32
|
-56.35
|
-16.57
|
-20.28
|
-22.21
|
-24.91
|
68.21
|
-18.62
|
-18.85
|
-18.27
|
Operating Margin
|
-45.77%
|
3.99%
|
-84.4%
|
-180.39%
|
-157.94%
|
59.55%
|
-50.58%
|
-49.46%
|
-50.46%
|
-58.35%
|
-59.45%
|
208.25%
|
-45%
|
-43.2%
|
-33%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-31.23
|
-32.12
|
-31.65
|
Net income
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-31.23
|
-32.12
|
-31.65
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-75.48%
|
-73.62%
|
-57.17%
|
EPS
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-0.1300
|
-0.1200
|
-0.2500
|
-0.2300
|
0.4100
|
-0.0800
|
-0.1100
|
-0.1000
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
04/08/20
|
03/02/22
|
05/05/22
|
11/08/22
|
11/08/22
|
10/11/22
|
23/03/23
|
04/05/23
|
21/09/23
|
09/11/23
|
21/03/24
|
07/05/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
82.7
|
77.8
|
94.2
|
116
|
Net Cash position
1 |
38.1
|
151
|
289
|
191
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-1.268
x
|
1.558
x
|
-3.875
x
|
-45.75
x
|
Free Cash Flow
1 |
-5.36
|
118
|
-16.3
|
-275
|
-217
|
-21.6
|
-1
|
3.44
|
ROE (net income / shareholders' equity)
|
-1.25%
|
-60.6%
|
-59.2%
|
-73.4%
|
-58.3%
|
16%
|
-37.9%
|
-17.9%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
1.490
|
0.8500
|
1.620
|
-
|
0.9300
|
1.240
|
0.8500
|
0.7100
|
Cash Flow per Share
2 |
0.0600
|
0.9500
|
-
|
-0.8600
|
-
|
-0.1000
|
-0.1000
|
0.1000
|
Capex
1 |
10.5
|
18.9
|
92.2
|
29.2
|
14.2
|
13.9
|
11.7
|
9.32
|
Capex / Sales
|
8.32%
|
17.17%
|
26.49%
|
8.09%
|
9.26%
|
7.34%
|
4.99%
|
2.9%
|
Announcement Date
|
27/02/20
|
25/02/21
|
03/02/22
|
23/03/23
|
21/03/24
|
-
|
-
|
-
|
Last Close Price
4.114
EUR Average target price
8.967
EUR Spread / Average Target +117.96% Consensus |
1st Jan change
|
Capi.
|
---|
| +43.36% | 5.46TCr | | -5.31% | 3.99TCr | | +14.75% | 2.69TCr | | -12.56% | 2.62TCr | | -22.45% | 1.88TCr | | +25.12% | 1.22TCr | | +0.04% | 1.22TCr | | +26.04% | 1.19TCr | | -11.83% | 1.07TCr |
Other Biotechnology & Medical Research
|